Navigation Links
AnaptysBio Expands Immunotherapy Portfolio With Anti-PD-1 Antibody Combinations
Date:8/29/2013

SAN DIEGO, Aug. 29, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the expansion of its proprietary immunotherapy antibody portfolio to include multiple new combination therapies.  Using its SHM-XEL platform, the Company has recently developed a proprietary anti-PD-1 antibody, known as ANB011, with key differentiating advantages over competitors.  AnaptysBio is concurrently developing novel antibodies against other immune checkpoint receptors, including TIM-3 and LAG-3, which may be applied in combination with ANB011. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

Antibodies to immune checkpoint receptors have recently demonstrated promise in the treatment of various solid tumors, including metastatic melanoma, renal cell carcinoma and non-small cell lung cancer.  Although the normal function of immune checkpoint receptors is to maintain immune homeostasis, they are co-opted by certain tumors to evade immune surveillance.  By blocking the interaction of PD-1, TIM-3 and LAG-3 with their respective ligands, AnaptysBio's immunotherapy portfolio aims to restore immune function in cancer patients across a variety of tumor types.   These antibodies may also be combined with small molecule kinase inhibitors for additional anti-tumor activity.    

In addition to the immunotherapy portfolio described above, AnaptysBio has utilized its SHM-XEL platform to develop a novel antibody pipeline, including programs for pustular psoriasis, atopic dermatitis, muscle wasting disorders, fibrosis and antibody drug conjugate applications.

"We believe combination immunotherapy is an exciting paradigm in oncology and has the potential to provide durable anti-tumor effects for a broad range of patients," said Hamza Suria, president & chief executive officer of AnaptysBio. "Our SHM-XEL platform has permitted us to rapidly generate high potency antibodies against multiple immune checkpoint receptors." 

About AnaptysBio

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. We are developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's proprietary SHM-XEL™ platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, stability, function, cross-reactivity, epitope diversity and manufacturability. The Company has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, DARPA and DTRA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit www.anaptysbio.com.

Contacts:
Julie Rathbun
julie@rathbuncomm.com
206-769-9219


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
2. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
3. AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
4. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
7. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. PRA Expands Operations in Europe
10. USANA Health Sciences Expands Award-Winning Research and Development Team
11. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):